Albany Molecular Research Inc. (NASDAQ:AMRI) traded down 1.5% during mid-day trading on Thursday . The stock traded as low as $14.80 and last traded at $14.83, with a volume of 102,588 shares changing hands. The stock had previously closed at $15.05.

Separately, Morgan Stanley reiterated a “buy” rating on shares of Albany Molecular Research in a research note on Sunday, May 8th.

The firm’s 50-day moving average is $14.46 and its 200-day moving average is $14.68. The company’s market cap is $511.37 million.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Thursday, August 4th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.04. The company earned $116.50 million during the quarter, compared to the consensus estimate of $123.10 million. Equities analysts anticipate that Albany Molecular Research Inc. will post $1.09 earnings per share for the current year.

In other Albany Molecular Research news, Director Kevin Oconnor sold 5,000 shares of Albany Molecular Research stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total value of $72,050.00. Following the completion of the sale, the director now directly owns 52,955 shares of the company’s stock, valued at $763,081.55. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

A hedge fund recently raised its stake in Albany Molecular Research stock. Ancora Advisors LLC increased its stake in shares of Albany Molecular Research Inc. (NASDAQ:AMRI) by 1.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 103,300 shares of the company’s stock after buying an additional 1,000 shares during the period. Ancora Advisors LLC owned about 0.30% of Albany Molecular Research worth $1,682,000 as of its most recent SEC filing.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.